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Research
apid changes in general practice
have increased possibilities to diag-
nose and manage chronic diseases
such as chronic obstructive pulmonary dis-
ease (COPD). Several national and interna-
tional guidelines for COPD are available1-4
to help general practitioners with this.
“Monitoring”, or regular surveillance of
patients’ health status, is a cornerstone of
COPD management.5 I put of specialist
knowledge into monitoring enables compar-
ison of the process and outcome of care with
evidence-based guidelines. It can also alert
GPs to areas in which individual patient care
falls short, and introduce explicit recom-
mendations for management. Our group has
demonstrated the effectiveness of expert-
supported monitoring on the outcome of
diabetes care in general practice.6
COPD management places a substantial
demand on medical resources,7,8 and patient
adherence is important to the success of
treatment.9 Any expert-supported respira-
tory monitoring system depends on the
cooperation of various groups (ie, GPs, spe-
cialists and patients), contains interacting
components, and is, therefore, a complex
intervention.10
We aimed to investigate the long-term
effectiveness of a primary care monitoring
system with respiratory expert recommen-
dations for GPs’ management of patients
with COPD, compared with usual care. We
performed a detailed process evaluation
along with the trial; elements of this evalu-
ation are also reported here.
METHODS
Study design
We conducted a multicentre parallel group
study with a 24-month patient follow-up
(www.clinicaltrials.gov NCT00542061).
The trial took place from July 2005 to
February 2008. We allocated general prac-
tices to intervention (ie, respiratory expert-
supported COPD monitoring system) or
usual care. All participants at each general
practice were allocated to the same treat-
ment group (cluster randomised design).
We hypothesised that ongoing half-yearly
monitoring with respiratory expert recom-
mendations of patients with COPD would
result in a clinically relevant gain in quality
of life compared with usual care.
The study protocol was approved by the
medical ethics committee of the Arnhem
Nijmegen region in the Netherlands. All
patients gave written informed consent.
Participants and sample size calculation
We selected and invited study participants
based on patient records already available at
a regional diagnostic centre (RDC) in the
south-western region of the Netherlands.
Inclusion criteria were:
• patient diagnosed with COPD or asthma
with persistent airflow obstruction, as con-
firmed with the patient’s most recent
spirometry (forced expiratory volume in 1
second [FEV1]/forced vital capacity [FVC]
< 70%, or postbronchodilator FEV1 < 80%
predicted and  9% reversibility);11,12
• the patient’s lung function data from the
previous year were available at the general
practice diagnostic centre; and
• patient aged at least 25 years.
Exclusion criteria were:
• patient treated by a chest physician;
• patient participating in another respira-
tory intervention study;
• GP considered it detrimental to the
patient to participate in the study;
• patient had any serious other non-
pulmonary diseases (or disease stages) or
pulmonary diseases (eg, sarcoidosis, lung
cancer, lung fibrosis); or
• patient could not read.
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ABSTRACT
Objective:  To investigate the long-term effectiveness of a general practice monitoring 
system with respiratory expert recommendations for general practitioners’ management 
of patients with chronic obstructive pulmonary disease (COPD), compared with usual care. 
Design, settings and participants:  A multicentre randomised controlled trial of 
patients with COPD, clustered by general practices; 200 participants were recruited 
to maintain at least 75 participants per group for analysis. The trial took place from July 
2005 to February 2008 in the south-western region of the Netherlands.
Intervention:  Ongoing half-yearly monitoring of COPD patients with respiratory expert 
recommendations for the GP was compared with usual care.
Main outcome measures:  Primary outcome — Chronic Respiratory Questionnaire 
(CRQ) score; secondary outcomes — CRQ domain scores, generic health-related quality 
of life (Short-Form 12 and EuroQol-5D), breathlessness (Modified Medical Research 
Council score), exacerbations, and decline in forced expiratory volume in 1 second. 
A detailed process evaluation was performed along with the trial.
Results:  Data from 170 participants were analysed. Based on repeated measurement 
analyses, the additional gain in CRQ score during follow-up was 0.004 points for 
monitoring compared with usual care (95% CI, −0.172 to 0.180). Also, no important 
differences between monitoring and the usual care group were found for secondary 
outcomes. Half the monitoring visits resulted in disease management recommendations 
by a respiratory expert, and 46% of these recommendations were implemented by the 
GPs. Patient adherence to lifestyle recommendations was low.
Conclusion:  An expert-supported monitoring system for patients with COPD was not 
clinically effective. As patients had a pre-existing entry in the monitoring system, the 
population may be well regulated, with reduced room for improvement.
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GPs at practices who had referred more
than six patients to the RDC were contacted
and asked to participate. We used compu-
terised minimisation to allocate practices to
the monitoring and usual care groups13,14
while stratifying for:
• group versus solo practice;
• practice nurse employed versus no prac-
tice nurse employed; and
•  10 versus > 10 patients fulfilling the
study inclusion criteria.
A multilevel power calculation (ie, correc-
tion for clustering of subjects within general
practices) was based on the mean difference
in change in Chronic Respiratory Question-
naire (CRQ) score between monitoring and
usual care. A difference of 0.5 points is
generally accepted as a minimum important
clinical difference for the CRQ score.15 We
initially aimed to recruit 100 participants
per group based on the following assump-
tions: an intracluster correlation coefficient
of 0.04; α= 0.05; 1 β = 0.80; and a drop-
out rate of 25%.
Blinding
In their study information letters, GPs and
patients were informed that patients were
invited for an unspecified number of visits
to the RDC. GPs were informed that partici-
pation could imply that the outcome of their
patients’ visits would not be forwarded to
them during the study as it had been previ-
ously. After minimisation, GPs received spe-
cific research information for their practice.
The respiratory experts involved and the
lung function technicians who performed
the spirometric tests and collected medical
information were not aware of patients’ par-
ticipation and allocation.
Intervention
The expert-supported COPD monitoring
system had been in use in the RDC since
1995, and comprised several steps.
Step A. Patients with COPD were invited to
the RDC for monitoring visits every 6
months. Pre- and post- (after inhaling
400 μg salbutamol) bronchodilator FEV1
and FVC were measured at each visit with a
SpiroPerfect spirometer (WelchAllyn, Delft,
The Netherlands) by certified lung function
technicians. Body mass index was assessed,
and information on respiratory symptoms,
exacerbations, smoking and medication use
in the previous 6 months was collected in a
standardised way.
Step B. Information from the monitoring
visit and previous visits was sent to a respir-
atory expert (chest physician or GP with
special respiratory interest). The respiratory
experts gave recommendations regarding
treatment, additional diagnostic tests and
referrals to other disciplines, based on
national clinical practice guidelines for
COPD and asthma.11,12 Experts’ interpreta-
tion based on spirometry results and written
information has been shown to be valid.16
Step C. Written feedback was sent to the
patient’s GP. The patient was instructed to
visit the GP 2 weeks after the monitoring
visit to discuss the outcome. During these
visits, the expert recommendations could be
implemented by the GP (eg, checking
inhalation technique) or recommended to
the patient. Half-yearly visits from a nurse
consultant to the practice to support GPs in
implementing the recommendations were
an integral part of the expert-supported
monitoring system.
Step D. Ultimately, the patient should
implement the recommendations made (eg,
quit smoking, increase exercise).
Usual care
We invited participants from the usual care
group for spirometry at the beginning and at
the end of the trial. No recommendations or
feedback were given, and no nurse consult-
ant practice visits were scheduled during the
study period.
Outcomes and process evaluation
Participants completed questionnaires at
baseline, at 1 year, and at the end of the
1 Flow chart of practice and participant recruitment, inclusion and drop-out
* According to the patient’s general practitioner. † Analyses were based on the intention-to-treat principle. ◆
56 general practices invited
22 practices refused to participate
34 general practices participated 
Practice allocation
by minimisation
Baseline visit 
Follow-up 
completed
Analysis
18 practices allocated to usual care 
219 patients
154 eligible patients
112 participants
97 participants
86 participants
88 participants†
16 practices allocated to intervention
185 patients
53 excluded — treated by chest physician (24); other disease (2); 
too old* (4); other reasons (23)
31 refused — personal reasons (8); lack of time (1); no transportation (2); 
no interest (2); other reasons (4); no explanation (4); no response (10)
9 did not enter study — treated by chest physician (2); 
severe comorbidity (2); personal reasons (4); other reasons (1)
10 dropouts — lack of time (1); age (1); comorbidity (4); no longer interested (1); 
referred to chest physician (2); missing (1) — 4 discontinued intervention
10 excluded from analysis — first questionnaire filled out too late (6); 
questionnaire missing (2); too many missing answers (2)
65 excluded — treated by chest physician (34); other disease (4); 
too old* (2); other reasons (25)
42 refused — personal reasons (10); lack of time (5); no interest (1); 
other reasons (5); no explanation (6); no response (15)
15 did not enter study — treated by chest physician (1); 
personal reasons (1); did not attend first lung function test (4); died (1); 
general practice stopped (5); other reasons (3)
11 dropouts — died (4); lack of time (1); comorbidity (2); 
no longer interested (2); personal circumstances (2)
9 excluded from analysis — first questionnaire filled out too late (4); 
questionnaire missing (3); too many missing answers (2)
132 eligible patients
101 participants
92 participants
82 participants
82 participants†
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study. The primary study outcome was the
CRQ score.17 Secondary outcomes were:
CRQ domain scores; generic health-related
quality of life (physical and mental domains
of the Short-Form 12 [SF-12] and the Euro-
Qol-5D);18-20 breathlessness according to
level of exertion (Modified Medical Research
Council [MMRC] score,2 dichotomised as
0–1 and 2–4); occurrence rate of self-
reported exacerbations; and annual FEV1
decline.
For the process evaluation, the respiratory
experts’ database was examined to collect
data on their recommendations. The nurse
consultant collected data on GPs’ implemen-
tation of recommendations. Patient ques-
tionnaires comprised questions about
disease management. At the end of the
study, the nurse consultant collected infor-
mation on disease management from GPs in
the usual care group.
Statistical analysis
Baseline characteristics for the participants
in each group were compared using
unpaired t tests, χ2 tests, and Mann–Whit-
ney U tests, depending on the type of
variable and normality of distribution.
Multi level  repeated measurement
regression analysis was used to model the
effect of monitoring on CRQ overall
score, CRQ domain scores, SF-12 scores,
EuroQol-5D scores, FEV1 decline, and
dichotomised MMRC scores. We used a
PROC MIXED procedure in SAS statistical
software (SAS Institute, Cary, NC, USA),
with general practice as the random coef-
ficient and compound symmetry correla-
t ion st ruc ture .  Mult i leve l  logis t ic
regression analysis was used to analyse
effects on exacerbations. All models were
corrected for sex, age, socioeconomic sta-
tus, baseline cigarette smoking status,
reversibility, exacerbations at baseline,
use of inhaled corticosteroids, use of
long-acting bronchodilators, and post-
bronchodilator FEV1 % of the predicted
value. Participants were included in the
analysis if they participated in the study
(intention-to-treat analysis).
RESULTS
Study population
Box 1 shows the process of practice and
patient recruitment and follow-up. Thirty-
four general practices participated. From
these, 261 of 286 eligible patients (91%)
responded to the invitation, and 213
(74%) were willing to participate. No
significant differences between partici-
pants and non-participants with regard to
sociodemographic characteristics, medi-
cation use, and spirometric indices were
found. Twenty-four patients did not enter
the study, and 19 patients were excluded
from analyses. Data from 170 participants
were used for the analyses. Box 2 shows
the baseline characteristics of both
groups.
The study was originally designed to eval-
uate monitoring of patients with COPD and
asthma with a chronic airflow obstruction.
However, after the recruitment phase we
found that almost all of the patients fulfilled
the criteria for COPD (ie, FEV1/FVC < 70%
postbronchodilator); therefore, we decided
to focus on COPD.
Clinical effectiveness of the expert-
supported monitoring system
Box 3 shows the mean overall CRQ scores in
the monitoring and usual care groups. Based
on repeated measurement analyses, the
additional gain in CRQ score during follow-
up was 0.004 points for monitoring com-
pared with usual care (95% CI, 0.172 to
0.180). Box 4 summarises the results for the
secondary outcomes. No significant differ-
ences between the monitoring and usual
care groups were observed other than CRQ
domain mastery.
Process evaluation
A total of 292 visits took place among the
monitoring group participants. Fifty-eight
participants attended all four planned moni-
toring visits at the RDC (71%). Fifteen
patients (18%) attended three, six patients
attended two, and three patients attended
one planned visit.
In total, respiratory experts gave 290 rec-
ommendations (Box 5). Smoking cessation
was the most frequent recommendation
(28% of all recommendations), and inhaler
technique training and assessment of com-
pliance with medical treatment were also
recommended regularly. In 146 monitoring
visits (50%), the respiratory experts did not
consider any modification in disease man-
agement necessary. For 73 patients (89%),
the GPs received at least one recommenda-
tion to change disease management.
Information about 274 of the 290 recom-
mendations could be collected (Box 5).
According to GPs, they attempted to imple-
ment 125 (46%) of the 274 recommenda-
2 Baseline characteristics 
of participants 
BD = bronchodilator. FEV1 = forced expiratory 
volume in 1 second. FVC = forced vital capacity. 
ICS = inhaled corticosteroids. MMRC = Modified 
Medical Research Council. * Difference between 
monitoring group and usual care group significant; 
P < 0.05. † Difference between monitoring group 
and usual care group significant; P < 0.01. ‡ One 
missing value. § Two missing values. ◆
Monitoring 
group 
(n = 82)
Usual care 
group 
(n = 88)
Age in years, 
mean (SD) 
62 (10.5) 64 (10.5)
Male 56* 47
Post-BD FEV1% of 
predicted 
70†‡ 77
Post-BD FEV1/FVC 61*
‡ 65
Short-acting BDs 33‡ 26
Long-acting BDs 52‡ 58
ICS 59‡ 65
Smoking
Yes 53† 40
No 6 18
Former smoker 23 30
Pack-years, 
mean (SD)
27.5 (21.8)* 20.7 (18.1)
MMRC score
0 11‡ 16
1 36 30
2 26 35
3 6 5
4–5 2 2
 1 exacerbations 
in past year
16§ 17
3 Mean CRQ score (95% CI) 
of expert-supported COPD 
monitoring compared with 
usual care at baseline and at 
1 and 2 years
COPD = chronic obstructive pulmonary disease. 
CRQ = Chronic Respiratory Questionnaire. ◆
5.8
C
R
Q
 s
co
re
5.6
5.4
5.2
5
0 1
Years
Monitoring group Usual care group
2
4.8
4.6
4.4
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tions. In practices with a practice nurse, the
implementation rate of recommendations
was higher than in practices without a prac-
tice nurse (P < 0.05); in particular, inhaler
technique training and checking medication
compliance were implemented more fre-
quently (Box 5). The main reason why
recommendations were not implemented
was because patients did not visit the prac-
tice after their monitoring visit at the RDC.
On 45 occasions, patients did not visit the
GP after a monitoring visit that had resulted
in at least one recommendation.
Changes in disease management are
shown in Box 6. In general, only minor
changes in disease management were
achieved in the monitoring group, and these
changes were comparable to usual care.
DISCUSSION
We did not find a clinical benefit for patients
who received ongoing care according to a
well structured respiratory expert-sup-
ported COPD monitoring system compared
with usual care by GPs. The adherence of
patients to the monitoring visits was good.
In half the cases, the respiratory experts felt
that disease management could be
improved, and almost half the recommenda-
5 Number of times a respiratory expert recommended each disease 
management change, and general practitioner adherence to 
recommendations overall and in practices with and without a practice nurse
Adherence = GP attempted to implement recommendation. BD = bronchodilator. ICS = inhaled 
corticosteroids. * Eleven recommendations were not discussed by GPs and three GPs’ responses were 
missing. † No. of GPs adhering to recommendation/no. of recommendations evaluated in each type of 
practice. ‡ Difference between practices with and without practice nurses is significant; P < 0.05 (χ2 test). ◆
Recommendation
Expert
recommend-
ations
Recommend-
ations 
evaluated*
GPs’ adherence
Overall
Practices 
with 
nurse†
Practices 
without 
nurse†
Cease smoking 82 78 44 25/47 19/31
Optimise physical condition 21 20 6 2/5 4/15
Avoid allergens and triggers 4 4 3 1/1 2/3 
Check inhaler technique 47 45 21 15/23 6/22 
Check treatment compliance 49 46 29 18/25 11/21
Reduce bodyweight 4 3 1 1/2 0/1
Introduce ICS 15 14 5 2/7 3/7 
Increase ICS dosage 6 6 3 1/2 2/4
Reduce dosage or cease ICS 10 10 6 6/10 0/0
Introduce short-acting BD 1 1 1 1/1 0/0
Introduce long-acting BD 10 8 0 0/4 0/4
Additional diagnostic procedures 3 3 0 0/2 0/1
Chest x-ray 14 13 3 1/8 2/5 
Refer to chest physician 24 23 3 1/9 2/14 
Total 290 274 125 74/146‡ 51/128
4 Effects of expert-supported chronic obstructive pulmonary disease monitoring compared with usual care on outcomes of 
respiratory health and quality of life
A. Mean (95% CI) at baseline, change (95% CI) at follow-up, and difference between groups (95% CI) for continuous variables 
B. Frequency (no. [%]) of categorical variables at baseline and follow-up, and odds ratios 
CRQ =Chronic Respiratory Questionnaire. SF-12=Short-Form 12. MICD=minimum important clinical difference. MMRC=Modified Medical Research Council.
*Monitoring versus usual care based on multilevel repeated measurement analysis corrected for sex, age, socioeconomic status, smoking status at baseline, reversibility, 
exacerbations at baseline, use of inhaled corticosteroids, use of long-acting bronchodilators, and postbronchodilator forced expiratory volume in 1 second % of predicted value. 
†Difference between monitoring and usual care is significant; P<0.05. ‡Two missing values. §Difference between monitoring and usual care is significant; P<0.01. 
¶One missing value. **Three missing values. ††Seven missing values. ‡‡ Monitoring versus usual care based on multilevel logistic regression analysis, corrected for covariates. ◆
Monitoring group Usual care group
Adjusted incremental 
2-year change* MICD
Baseline
(n = 82)
Change at 2-year 
follow-up (n = 76)
Baseline
(n = 88)
Change at 2-year 
follow-up (n = 80)
Overall CRQ score 5.1 (4.9 to 5.3) 0.12 (−0.02 to 0.26) 5.3 (5.2 to 5.5) 0.12 (0.00 to 0.24)
CRQ domain dyspnoea 4.9 (4.6 to 5.3)† 0.30 (0.10 to 0.50) 5.4 (5.1 to 5.7)‡ 0.29 (0.07 to 0.50)‡ 0.018 (−0.24 to 0.27) 0.5
CRQ domain fatigue 4.9 (4.7 to 5.2) −0.09 (−0.32 to 0.13) 5.1 (4.9 to 5.3) 0.13 (−0.09 to 0.34) −0.236 (−0.54 to 0.07) 0.5
CRQ domain emotions 5.4 (5.2 to 5.6) 0.08 (−0.11 to 0.27) 5.5 (5.3 to 5.7) 0.09 (−0.06 to 0.24) −0.005 (−0.26 to 0.25) 0.5
CRQ domain mastery 4.8 (4.7 to 5.0)§ 0.17 (0.02 to 0.33) 5.1 (4.9 to 5.3) −0.03 (−0.16 to 0.11) 0.223† (0.02 to 0.42) 0.5
SF-12 physical scale 44.5 (43.0 to 46.1)¶ −1.44 (−2.98 to 0.10)‡ 43.8 (42.3 to 45.4)** −0.16 (−1.73 to 1.42)†† −1.323 (−3.40 to 0.75) 3–5
SF-12 mental scale 52.2 (50.2 to 54.1)¶ 0.09 (−1.85 to 2.03)‡ 52.7 (51.1 to 54.2)** −0.23 (−1.94 to 1.49)†† 0.324 (−2.24 to 2.89) 3–5
EuroQol-5D score 0.89 (0.86 to 0.92) −0.02 (−0.05 to 0.01) 0.87 (0.84 to 0.89) 0.00 (−0.03 to 0.03) −0.022 (−0.07 to 0.02) 0.07
Monitoring group Usual care group Odds ratio 
(95% CI)Baseline (n = 82) 2-year follow-up (n = 76) Baseline (n = 88) 2-year follow-up (n = 80)
MMRC score  2 8 (9.9%)¶ 12 (15.8%) 7 (8.0%) 10 (12.7%)¶ 1.05 (0.34–3.24)
 1 exacerbations in previous year 16 (20.0%)‡ 12 (15.8%) 17 (19.8%)‡ 10 (12.7%)¶ 0.87‡‡ (0.38–2.11)
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tions by respiratory experts were imple-
mented by GPs. Non-adherence of patients
to visiting the GPs and making lifestyle
changes, and the low adherence of GPs to
some recommendations (eg, referral to chest
physician, chest x-ray) were the main barri-
ers to the implementation of the expert
recommendations.
All patients who were invited had previ-
ously visited the diagnostic centre for at least
one lung function assessment. It may be
argued that we did not find effects in the
study because we studied the effect of moni-
toring on a population with pre-existing
entry into the monitoring system, rather than
the effect of monitoring on a newly diag-
nosed population. Essentially, we compared
health effects in a control group that had
discontinued monitoring with those in the
treatment group that had continued and
intensified monitoring. This might have
resulted in less “room for improvement”
compared with a “naïve” population of
COPD patients. The inclusion of newly diag-
nosed patients could have resulted in better
clinical results. However, our aim was to
determine the long-term usefulness of dis-
ease monitoring. The evaluated monitoring
system has already been implemented on a
large scale in the Netherlands, and after
patients with COPD have entered the serv-
ice, they are usually followed for many years.
Our results indicate that keeping an expert-
supported monitoring system in place for
years appears not to benefit COPD patients.
Moreover, it was not possible to blind GPs
and patients in this study, as information on
process and outcome was reported by them.
Patients who are aware of their treatment
assignment may expect certain benefits that
may influence the outcome, especially when
the outcome is influenced by individual opin-
ions, as with quality of life. However, moni-
toring group participants reported no higher
health-related quality-of-life scores compared
with usual care group participants.
As far as we are aware, this is the first time
the effectiveness of a COPD expert-sup-
ported monitoring system has been evalu-
ated. However, other programs that focus on
monitoring, like an integrated COPD and/or
asthma management care model, a GP feed-
back system, and monitoring of health-
related quality of life of patients with asthma
and COPD, also did not result in clinical
benefits, although some improvements in
patient satisfaction and process outcomes
were found.21-24 Other monitoring systems,
such as monitoring of COPD by respiratory
nurses in a general practice or a “patient-
tailored” monitoring system, should be
explored. Moreover, more information on
the initial effect of the expert-supported
monitoring system in newly diagnosed
patients is needed (ie, including patients
who were not already known to the RDC). It
may be that the support system is able to
put COPD management on track, and that
after this initial support, GPs are sufficiently
equipped to manage the patients.
The question remains whether the lack of
effect was due to implementation failure —
and therefore the system has the potential to
be effective if implementation could be
improved — or was a result of an ineffective
intervention.10 Many participants failed to
visit the GP, although the adherence rate to
GP visits was significantly higher in general
practices that invited patients for regular
visits. Moreover, the presence of a practice
nurse resulted in higher implementation
levels. Therefore, implementation can be
improved, but it is not possible to fully
prevent dilution of effects in the process of
monitoring and feedback. Options to reduce
disease progression are  limited in
COPD.25,26 Moreover, little evidence exists
that chronic disease management in primary
care patients with COPD is effective.27
Potential effects are further diminished by
the low adherence of the participants to
health behaviour recommendations, which
is in concordance with other studies.25,28
In conclusion, an ongoing respiratory
expert-supported monitoring system for
patients with COPD was not effective in
terms of clinical outcomes. The lack of
effectiveness may have been the result of a
combination of limited options to intervene,
the diluting effect on the intervention
caused by the many steps in this complex
process, and the low adherence of patients
to crucial recommendations such as smok-
ing cessation.
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6 Chronic obstructive pulmonary disease management by general practitioners 
and patients in the second year of the study
Monitoring group (n = 82) Usual care group (n = 86)
Recommend-
ations*
Implement-
ation†
Recommend-
ations*
Implement-
ation†
Cease smoking‡ 14 3 13 0
Increase bodyweight 1 1§ 0 —
Reduce bodyweight 16 0§ 12 0§
Increase physical exercise 13 na¶ 7 na¶
Check treatment compliance — 22* — 20*
Check inhaler technique — 14* — 18*
Introduce/increase ICS dosage** — 4 — 5
Reduce dosage or cease ICS** — 4 — 3
Introduce short-acting BD** — 7 — 5
Introduce long-acting BD** — 11 — 8
Chest x-ray** — 6 — 5
Refer to chest physician 9 9*† 6 6*
BD = bronchodilator. ICS = inhaled corticosteroids. na = not applicable. Recommendations = by GPs. 
In monitoring group, these were based on expert recommendation or own initiative.
* According to the patient. † Implementation of recommendations by the patient. ‡ Patient stopped smoking 
according to the last questionnaire and medical information of the last visit to the regional diagnostic centre. 
§ ±3 kg bodyweight change according to measurement during lung function visits. ¶ Information on exercise 
tolerance was not collected. ** According to GPs’ electronically recorded information (nine missing values in 
monitoring group; 10 missing values in usual care group). ◆
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July MJA BookClub Winner
Congratulations to Dr Jenny Draper 
from Wingham, NSW. Dr Draper wins 
a copy of Paediatric Handbook (RRP 
$64.95). Thanks to everyone who 
purchased books from the July MJA 
BookClub. Pictured right is Yasmin 
Stein, AMPCo’s Editorial Assistant, 
who drew the July winner. To see this 
month’s MJA BookClub’s great offers, 
see page 279 and the inside back 
cover of this issue or visit our 
online bookshop at: 
http://shop.mja.com.au
